Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.64 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.62 |
| ▸ | SRC | P12931 | 4/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.59 |
| ▸ | GAK | O14976 | 1/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | STK10 | O94804 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.59 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.59 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.59 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8813398 | 0.80 | EGFR (0.67) | EGFRABL1PDGFRBFGFR1SRC | |
| Hydrochloric Acid SCHEMBL8809787 | 0.80 | EGFR (0.67) | EGFRABL1PDGFRBFGFR1SRC | |
| Hydrochloric Acid SCHEMBL8809541 | 0.79 | EGFR (0.65) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL8872136 | 0.78 | EGFR (0.74) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL6797080 | 0.78 | EGFR (0.81) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL12696080 | 0.77 | EGFR (1.00) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL7465236 | 0.76 | EGFR (0.58) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL16156117 | 0.76 | EGFR (0.57) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL1507604 | 0.75 | EGFR (0.87) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL21967048 | 0.75 | EGFR (0.76) | EGFRABL1PDGFRBFGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | claimed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | claimed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | claimed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150031695-A1 | SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS | BROOKS MICHAEL WEST (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2013158482-A1 | SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS | BROOKS MARVIN B (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281448-A1 | SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS | BROOKS FAMILY TRUST | 2013-10-24 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006089015-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | EGFR 1/4885ABL1 717/4885PDGFRB 381/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ABL1 64/4885PDGFRB 59/4885 |
| US-20150031695-A1 | SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS | TYK2, PTGES2, PAK2 | EGFR 223/4885ABL1 2915/4885PDGFRB 1395/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | EGFR 1/4885ABL1 717/4885PDGFRB 381/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | EGFR 2/4885ABL1 64/4885PDGFRB 59/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885ABL1 22/4885PDGFRB 14/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885ABL1 22/4885PDGFRB 14/4885 |
| US-20130281448-A1 | SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS | TYK2, PTGES2, KRAS | EGFR 131/4885ABL1 2982/4885PDGFRB 1197/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ABL1 64/4885PDGFRB 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.